Indivior Appoints Tony Kingsley as Non-Executive Director

An update from Indivior ( (INDV) ) is now available.

On June 24, 2025, Indivior PLC announced the appointment of Tony Kingsley as a non-executive director, effective July 1, 2025. Kingsley, an accomplished biopharmaceutical executive, is expected to bring significant commercial and clinical development experience to Indivior, enhancing its efforts to advance its mission and strengthen its position in delivering treatments for opioid use disorder. His appointment aligns with Indivior’s relationship agreement with affiliates of Oaktree Capital Management, and he will be compensated in line with other non-executive directors.

The most recent analyst rating on (INDV) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Spark’s Take on INDV Stock

According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.

Indivior’s overall score reflects strong technical momentum and improving financial performance, tempered by valuation concerns and negative trends from the earnings call. The stock’s momentum is a key strength, while balance sheet weaknesses and revenue declines present significant risks.

To see Spark’s full report on INDV stock, click here.

More about Indivior

Indivior is a global pharmaceutical company dedicated to developing medicines for treating opioid use disorder (OUD). With a vision to make evidence-based treatment accessible worldwide, Indivior aims to transform OUD from a global crisis into a recognized chronic disease. Headquartered in Richmond, VA, the company employs over 1,000 individuals and offers its products in over 30 countries.

Average Trading Volume: 1,017,260

Technical Sentiment Signal: Buy

Current Market Cap: $1.75B

Learn more about INDV stock on TipRanks’ Stock Analysis page.